

CLAIMS

1. An antibody-recruiting molecule (ARM),

wherein the ARM comprises an antibody binding moiety that can bind to one or more antibodies or fragments thereof, a target-binding moiety that can bind to the cell, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety for use in a method of inducing cell death, inhibiting cell growth and/or reducing the number of cells in a system; wherein the antibody-recruiting molecule (ARM) is to be administered into the system, and wherein a plurality of natural killer cells is to be optionally administered into the system;

so that the system is exposed to both and the number of cells in the system is reduced compared to absence of both the natural killer cells and the antibody-recruiting molecule.

2. An antibody-recruiting molecule (ARM),


wherein the ARM comprises an antibody binding moiety that can bind to one or more antibodies or fragments thereof, a target-binding moiety that can bind to the cancer cells, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety, for use in a method for treating a condition, disorder or disease the method, wherein the antibody-recruiting molecule (ARM) is to be administered to a subject suffering from the condition, disorder, or disease with a plurality of natural killer cell.

3. The antibody-recruiting molecule (ARM), of claim 2, wherein the condition, disorder or disease is cancer.

4. An antibody-recruiting molecule (ARM),

wherein the ARM comprises an antibody binding moiety that can bind to one or more antibodies or fragments thereof, a target-binding moiety that can bind to a target entity of the treatment, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety for use in a method of reducing side effects of a treatment using natural killer cells in a subject, wherein the antibody-recruiting molecule (ARM) is to be administered to the subject with a plurality of natural killer cells.

5. An antibody-recruiting molecule (ARM),
wherein the ARM comprises an antibody binding moiety that can bind to one or more antibodies or fragments thereof, a target-binding moiety that can bind to a target entity of the treatment, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety for use in a method of reducing toxicity of a treatment using natural killer cells in a subject, wherein the antibody-recruiting molecule (ARM) and a plurality of natural killer cells is to be administered to the subject.
6. The ARM for use according to any one of the preceding claims, wherein the ARM is to be administered with a plurality of natural killer cells to the subject, wherein the natural killer cells are memory-like natural killer cells.
7. The ARM for use according to any one of claims 1-5, the wherein the ARM is to be administered with a plurality of natural killer cells to the subject, wherein the natural killer cells are cytokine-induced memory-like natural killer cells induced by IL-12, IL-15 and IL-18.
8. The ARM for use according to claim 6 or 7, wherein the ARM is to be administered with a plurality of natural killer cells to the subject, and wherein the natural killer cells and the ARM are to be administered concurrently, optionally in one composition.
9. The ARM for use according to claim 6, the ARM is to be administered with a plurality of natural killer cells to the subject and wherein the natural killer cells are to be administered prior to or subsequently to the ARM.
10. The ARM for use according to claim 6, wherein the antibody binding moiety of the ARM is a universal antibody binding moiety.
11. The ARM for use according to claim 6, wherein the ARM is a compound of formula I:



I


or a pharmaceutically acceptable salt thereof, wherein:

ABT is an antibody binding moiety;

L is a bivalent linker moiety that connects ABT with TBT; and

TBT is a target binding moiety.

12. The ARM for use according to claim 6, wherein the ARM is a compound of formula **II**:



II

or a pharmaceutically acceptable salt thereof, wherein:

each of R¹, R³ and R⁵ is independently hydrogen or an optionally substituted group selected from C₁₋₆ aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or:

R¹ and R^{1'} are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R³ and R^{3'} are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

an R^5 group and the $R^{5'}$ group attached to the same carbon atom are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

two R^5 groups are optionally taken together with their intervening atoms to form a C_{1-10} bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-3 methylene units of the chain are independently and optionally replaced with $-S-$, $-SS-$, $-N(R)-$, $-O-$, $-C(O)-$, $-OC(O)-$, $-C(O)O-$, $-C(O)N(R)-$, $-N(R)C(O)-$, $-S(O)-$, $-S(O)_2-$, or $-Cy^1-$, wherein each $-Cy^1-$ is independently a 5-6 membered heteroarylenyl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;


each of $R^{1'}$, $R^{3'}$ and $R^{5'}$ is independently hydrogen or C_{1-3} aliphatic;

each of R^2 , R^4 and R^6 is independently hydrogen, or C_{1-4} aliphatic, or:

R^2 and R^1 are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;


R^4 and R^3 are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

an R^6 group and its adjacent R^5 group are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;




L^1 is a trivalent linker moiety that connects

and




L^2 is a covalent bond or a C_{1-10} bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-3 methylene units of the chain are independently and optionally replaced with $-S-$, $-N(R)-$, $-O-$, $-C(O)-$, $-OC(O)-$, $-C(O)O-$, $-C(O)N(R)-$, $-N(R)C(O)-$, $-S(O)-$,



TBT is a target binding moiety; and

each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or

wherein the ARM is a compound of formula **III**:




III

or a pharmaceutically acceptable salt thereof, wherein:

each of R^7 is independently hydrogen or an optionally substituted group selected from C_{1-6} aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or:

an R^7 group and the $R^{7'}$ group attached to the same carbon atom are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms

independently selected from nitrogen, oxygen, or sulfur;
 each of $R^{7'}$ is independently hydrogen or C_{1-3} aliphatic;
 each of R^8 is independently hydrogen, or C_{1-4} aliphatic, or:
 an R^8 group and its adjacent R^7 group are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
 R^9 is hydrogen, C_{1-3} aliphatic, or $-C(O)C_{1-3}$ aliphatic;




L^3 is a bivalent linker moiety that connects

TBT is a target binding moiety; and

o is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

13. The ARM for use according to claim 6, wherein the ARM is a compound having the structure of formula **I-a**:



or a salt thereof, wherein:

each Xaa is independently an amino acid residue;

t is 0-50;

z is 1-50;

L is a linker moiety;

TBT is a target binding moiety;

each R^c is independently $-L^a-R'$;

each of a and b is independently 1-200;

each L^a is independently a covalent bond, or an optionally substituted bivalent group selected C_1-C_{20} aliphatic or C_1-C_{20} heteroaliphatic having 1-5 heteroatoms, wherein one or more

methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent group selected from a C_{3-20} cycloaliphatic ring, a C_{6-20} aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;


each R' is independently $-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or wherein the ARM is a compound having the structure of formula **I-b**:



I-b

or a salt thereof, wherein:

each Xaa is independently an amino acid residue;

each z is independently 1-50;

each L is independently a linker moiety;

TBT is a target binding moiety,

each R^c is independently $-L^a-R'$;

each of a1 and a2 is independently 0-200, wherein at least one of a1 and a2 is not 0;

b is 1-200;

each L^a is independently a covalent bond, or an optionally substituted bivalent group selected C_1 - C_{20} aliphatic or C_1 - C_{20} heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent group selected from a C_{3-20} cycloaliphatic ring, a C_{6-20} aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R' is independently $-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond,
or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered,

monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

14. The ARM for use according to claim 6, wherein the ARM is to be administered with an antibody or a fragment thereof.

15. The ARM for use according to claim 6, wherein the antibody binding moiety is or comprises a peptide unit that is or comprises DCAWHLGELVWCT, wherein the two cysteine residues optionally form a disulfide bond.

16. The ARM for use according to claim 6, wherein the antibody binding moiety is or comprises a peptide unit that is or comprises CDCAWHLGELVWCTC, wherein the first and the last cysteines, and the two cysteines in the middle of the sequence, each independently and optionally form a disulfide bond.

17. A combination comprising:
a plurality of natural killer cells; and
an antibody-recruiting molecule (ARM), wherein:
the ARM comprises an antibody binding moiety that can bind to one or more antibodies, or fragments thereof, a target-binding moiety that can bind to a target entity, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety.

18. The combination of claim 17, wherein the natural killer cells are natural killer cells of any one of claims 1-16, and/or the ARM is an ARM of any one of claims 1-16.


19. A composition comprising:
a plurality of natural killer cells; and
an antibody-recruiting molecule (ARM), wherein:
the ARM comprises an antibody binding moiety that can bind to one or more antibodies, or fragments thereof, a target-binding moiety that can bind to a target entity, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety.

20. The composition of claim 19, wherein the natural killer cells are natural killer cells of any one of claims 1-5, and/or the ARM is an ARM of any one of claims 1-5.

21. The composition of claim 19 or 20, wherein the composition comprises an antibody or a fragment thereof.

22. The anti-body recruiting molecule (ARM) or combination of any one of Embodiments 1-103.

23. An anti-body recruiting molecule (ARM) of formula **I-a**:



or a salt thereof, wherein:

each Xaa is independently an amino acid residue;

t is 0-50;

z is 1-50;

L is a linker moiety;

TBT is a target binding moiety;

each R^c is independently $-L^a-R'$;

each of a and b is independently 1-200;

each L^a is independently a covalent bond, or an optionally substituted bivalent group selected C_1 - C_{20} aliphatic or C_1 - C_{20} heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent group selected from a C_{3-20} cycloaliphatic ring, a C_{6-20} aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R' is independently -R, -C(O)R, -CO₂R, or -SO₂R;

each R is independently -H, or an optionally substituted group selected from C₁₋₃₀ aliphatic, C₁₋₃₀ heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C₆₋₃₀ aryl, C₆₋₃₀ arylaliphatic, C₆₋₃₀ arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

24. The ARM of claim 23, wherein a is 1 and b is 1.

25. The ARM of claim 23 or 24, wherein -(Xaa)_z- is or comprises -X³X⁴X⁵X⁶X⁷X⁸X⁹X¹⁰X¹¹X¹²-, wherein:

each of X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, and X¹² is independently an amino acid residue;

X⁶ is Xaa^A or Xaa^P;

X⁹ is Xaa^N; and

X¹² is Xaa^A or Xaa^P,

wherein each Xaa^A is independently an amino acid residue whose side chain comprises an aromatic group, each Xaa^P is independently an amino acid residue whose side chain comprises a positively charged side chain, and each Xaa^N is independently an amino acid residue whose side chain comprises a negatively charged side chain.

26. The ARM of claim 23 or 24, wherein $-(\text{Xaa})_z-$ is or comprises

$-\text{X}^3\text{X}^4\text{X}^5\text{X}^6\text{X}^7\text{X}^8\text{X}^9\text{X}^{10}\text{X}^{11}\text{X}^{12}-$, wherein:

at least two amino acid residues are connected through one or more linkages L^b ;

L^b is an optionally substituted bivalent group selected C_1 - C_{20} aliphatic or C_1 - C_{20} heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-\text{C}(\text{R}')_2-$, $-\text{Cy}-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}-\text{S}-$, $-\text{N}(\text{R}')-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{S})-$, $-\text{C}(\text{NR}')-$, $-\text{C}(\text{O})\text{N}(\text{R}')-$, $-\text{N}(\text{R}')\text{C}(\text{O})\text{N}(\text{R}')-$, $-\text{N}(\text{R}')\text{C}(\text{O})\text{O}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})_2\text{N}(\text{R}')-$, $-\text{C}(\text{O})\text{S}-$, or $-\text{C}(\text{O})\text{O}-$, wherein L^b is bonded to a backbone atom of one amino acid residue and a backbone atom of another amino acid residue, and comprises no backbone atoms;

X^6 is Xaa^{A} or Xaa^{P} ;

X^9 is Xaa^{N} ;





X^{12} is Xaa^{A} or Xaa^{P} ; and







wherein each Xaa^{A} is independently an amino acid residue whose side chain comprises an aromatic group, each Xaa^{P} is independently an amino acid residue whose side chain comprises a positively charged side chain, and each Xaa^{N} is independently an amino acid residue whose side chain comprises a negatively charged side chain.





27. The ARM of any one of claims 23 to 26, wherein each of X^4 , X^7 , and X^{11} is independently an amino acid residue with a hydrophobic side chain (“hydrophobic amino acid residue”, Xaa^{H}).





28. The ARM of claim 23 or 24, wherein $(\text{Xaa})_z$ is or comprises DCAWHLGELVWCT, wherein the two cysteine residues optionally form a disulfide bond.





29. An anti-body recruiting molecule (ARM), of claim 23 or 24, wherein $(\text{Xaa})_z$ is or comprises any one of





	
A-10	A-11
	
A-12	A-13





	
A-14	A-15
	
A-16	A-17
	





A-18	A-19
	
A-20	A-21
	
A-22	A-23





	
A-24	A-25
	
A-26	A-27



	
A-28	A-29
	
A-30	A-31

	
A-32	A-33
	
A-34	A-35


	
A-36	A-37
	
A-38	A-39

	
A-40	A-41
	
A-42	A-43


	
A-44	A-45
	
A-46	A-47

	
A-48	A-49


30. An anti-body recruiting molecule (ARM), selected from:





(I-9);




(I-10);




(I-11);








(I-14);




(I-15);







(I-18);







(I-19);



























or



31. An anti-body recruiting molecule (ARM), of the formula:

